Cargando…

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

INTRODUCTION: Doravirine (DOR) is an investigational NNRTI (aka MK-1439) that retains activity against common NNRTI-resistant mutants. We have previously reported the Part 1 results from a two-part, randomized, double-blind, Phase IIb study in ART-naïve HIV-1-positive patients [1]. At doses of 25, 5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatell, Josep M, Morales-Ramirez, Javier O, Hagins, Debbie P, Thompson, Melanie, Keikawus, Arasteh, Hoffmann, Christian, Rugina, Sorin, Osiyemi, Olayemi, Escoriu, Simona, Dretler, Robin, Harvey, Charlotte, Xu, Xia, Teppler, Hedy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Oral Presentation – Abstract O434
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224904/ https://www.ncbi.nlm.nih.gov/pubmed/25394041 http://dx.doi.org/10.7448/IAS.17.4.19532

Ejemplares similares

Profile of cardiovascular manifestations in COVID-19 patients at the Libreville university hospital center, Gabon
por: Ayo Bivigou, E., et al.
Publicado: (2022)

COVID-19 chez les patients cancéreux : risque, caractéristiques cliniques et prise en charge
por: Fehri, S. Majdoub, et al.
Publicado: (2023)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
por: Orkin, Chloe, et al.
Publicado: (2020)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials
por: Ait-Khaled, Mounir, et al.
Publicado: (2020)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

A post‐partum single‐dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre‐partum ZDV and intrapartum single‐dose nevirapine to prevent mother‐to‐ child HIV‐1 transmission
por: Samuel, Reshmi, et al.
Publicado: (2015)

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
por: Thompson, Melanie, et al.
Publicado: (2018)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
por: Ramón Santos, José, et al.
Publicado: (2014)

Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women
por: Hurwitz, Kathleen E., et al.
Publicado: (2023)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
por: Sanchez, Carlos Alberto, et al.
Publicado: (2010)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

EFICÁCIA E TOXICIDADE DE TENOFOVIR (TDF) E ENTRICITABINA (FTC) PARA INFECÇÕES LEVE A MODERADA PELO SARS-COV-2
por: de Arruda, Erico Antonio Gomes, et al.
Publicado: (2022)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
por: Pilkington, Victoria, et al.
Publicado: (2018)

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)
por: Defechereux, Patricia A., et al.
Publicado: (2015)

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2018)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Kumar, Princy, et al.
Publicado: (2018)

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Johnson, Margaret, et al.
Publicado: (2019)

Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study
por: Cooper, V, et al.
Publicado: (2010)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

1439. Latent tuberculosis infection treatment location and association with care completion
por: Campbell, Jeffrey, et al.
Publicado: (2022)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_156ak6dh0daobjvev10m7ls0l2